You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 17, 2020

Practical Law Life Sciences Global Guide: Pharmaceutical IP and Competition Law in Thailand (November 2020)

Subscribe to Updates
Thomson Reuters Practical Law

The Thailand updates to Practical Law’s Life Sciences Global Guide  have been released online, with legal practitioners from Tilleke & Gibbins contributing the Pharmaceutical Intellectual Property and Competition Law section.

The guide is a Q&A-style overview of the regulatory frameworks of the life sciences industries across multiple jurisdictions worldwide, with this chapter addressing the following issues as they relate to Thailand:

  • Pharmaceutical patent legislation and scope of protection
  • Patent application process, duration of protection, and revocation
  • Patent infringement, claims, and remedies
  • Non-patent barriers to competition for pharmaceutical protection
  • Pharmaceutical trademark legislation and scope of protection
  • Trademark application process, duration of protection, and revocation
  • Trademark infringement, claims, and remedies
  • Regulatory powers and enforcement against pharmaceutical counterfeiting
  • Competition law framework and implications for the pharmaceutical sector
  • Competition issues related to licensing of pharmaceutical technology and patents, and market entry of generic products
  • Market dominance issues in the pharmaceutical sector
  • Parallel imports
  • Foreign patent and trademark licenses, and payment of royalties

The full Pharmaceutical Intellectual Property and Competition Law in Thailand chapter can be accessed on the Practical Law website.

Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. Tilleke & Gibbins also drafted an updated chapter on Medicinal Product Regulation and Product Liability in Thailand, which Practical Law has published in its Life Sciences Global Guide  at the same time.

Related Professionals

Industries

Life Sciences

Practices

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

September 3, 2019
On February 19, 2019, by amending the Narcotics Act B.E. 2522, Thailand caught the cannabis industry by surprise and became the first Asia-Pacific country to legalize medicinal cannabis. While hemp had been approved for use in industry since 2018 (see here), the amendment of the Narcotics Act B.E. 2522, providing for a Thai FDA registration pathway for medicinal cannabis, was largely unexpected.   
Read More
May 21, 2019
On April 16, 2019, the Drug Act (No. 6) B.E. 2562 was published in the Government Gazette, amending the previous drug registration processes, clinical research processes, and fee schedules. The changes will apply to all pending applications and those filed from October 13, 2019 onward.New Requirements for RegistrationAn additional requirement has been added to the registration process for new drugs. Along with the drug registration dossier, the following documents must now be submitted for each drug classification:
Read More
April 23, 2019
Due to significant changes to the intellectual property (IP) landscape, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) indeed poses major challenges to Vietnam in implementing its obligations. Most of the obligations aim to enhance protection for IP proprietors. This will have a particular impact on the life science sectors, benefitting foreign pharmaceutical and agrochemical companies but reducing opportunities, at least in the short-term, for Vietnamese companies.
Read More
April 23, 2019
The market for ­pharmaceuticals in Vietnam is developing rapidly, in step with the country’s growing and aging population, rising per capita income, and increasing awareness of foreign ­brand-name drugs, which many ­Vietnamese consumers consider to be more reliable than generics and local brands. ­Naturally, Vietnam has ­become an attractive ­investment ­destination for ­foreign pharmaceutical companies eager to ­target new ­customers.
Read More